Literature DB >> 12370499

TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy.

Bridget Maher1, Ana Alfirevic, F Javier Vilar, Edmund G L Wilkins, B Kevin Park, Munir Pirmohamed.   

Abstract

OBJECTIVE: The pathogenic mechanisms underlying lipodystrophy in HIV-positive patients are largely unknown. TNF-alpha has many actions that are consistent with the features of lipodystrophy; therefore, an analysis was carried out to determine whether functionally active polymorphisms in the promoter region of the TNF-alpha gene are associated with the development of lipodystrophy.
DESIGN: Genetic case-control association study.
METHODS: Individuals were genotyped for the -238 and -308 polymorphisms in the TNF-alpha gene using polymerase chain reaction-restriction fragment length polymorphism analysis. The genotype and allele frequencies for 61 HIV-positive patients with lipodystrophy were compared with (a) 35 HIV-positive patients with no evidence of lipodystrophy and (b) 239 healthy HIV-negative individuals.
RESULTS: The frequency of the variant rare -238 allele was significantly different (P = 0.01) in HIV-positive patients with lipodystrophy than in those without lipodystrophy. At the genotype level, a trend towards a difference between patients with and without lipodystrophy was observed (chi2 for linear trend 5.2, P = 0.02). For the -308 polymorphism, no difference was found in genotype and allele frequencies between HIV patients with and without lipodystrophy.
CONCLUSIONS: The data suggest that the -238 (but not the -308) promoter region TNF-alpha gene polymorphism is a determinant in the development of HIV-related lipodystrophy. However, the results need to be confirmed in larger numbers of patients as well as in an ethnically diverse population. Copyright 2002 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12370499     DOI: 10.1097/00002030-200210180-00005

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  20 in total

Review 1.  [Adverse effects of antiretroviral therapy. Aspects of pathogenesis].

Authors:  U Seybold; R Draenert; F D Goebel
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

Review 2.  Adverse drug reactions: back to the future.

Authors:  Munir Pirmohamed; B Kevin Park
Journal:  Br J Clin Pharmacol       Date:  2003-05       Impact factor: 4.335

3.  The cellular structure and lipid/protein composition of adipose tissue surrounding chronically stimulated lymph nodes in rats.

Authors:  Christine A Mattacks; Dawn Sadler; Caroline M Pond
Journal:  J Anat       Date:  2003-06       Impact factor: 2.610

Review 4.  Pharmacogenetics as a tool to tailor antiretroviral therapy: A review.

Authors:  Antonio Aceti; Laura Gianserra; Lara Lambiase; Alfredo Pennica; Elisabetta Teti
Journal:  World J Virol       Date:  2015-08-12

5.  Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.

Authors:  Victor Asensi; Julio Collazos; Eulalia Valle-Garay
Journal:  World J Virol       Date:  2015-08-12

6.  Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy.

Authors:  Pere Domingo; M Carmen Cabeza; Alain Pruvost; Ferran Torres; Juliana Salazar; M del Mar Gutierrez; M Gracia Mateo; Angels Fontanet; Irene Fernandez; Joan C Domingo; Francesc Villarroya; Francesc Vidal; Montserrat Baiget
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

7.  European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142.

Authors:  Todd Hulgan; Richard Haubrich; Sharon A Riddler; Pablo Tebas; Marylyn D Ritchie; Grace A McComsey; David W Haas; Jeffrey A Canter
Journal:  AIDS       Date:  2011-01-02       Impact factor: 4.177

8.  Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro.

Authors:  Peter L Anderson; Tracy King; Jia-Hua Zheng; Samantha MaWhinney
Journal:  J Antimicrob Chemother       Date:  2008-06-20       Impact factor: 5.790

9.  Genetic analysis implicates resistin in HIV lipodystrophy.

Authors:  Koustubh Ranade; William J Geese; Mustafa Noor; Oliver Flint; Pablo Tebas; Kathleen Mulligan; William Powderly; Steven K Grinspoon; Michael P Dube
Journal:  AIDS       Date:  2008-08-20       Impact factor: 4.177

10.  Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients.

Authors:  B Lindegaard; P Keller; H Bruunsgaard; J Gerstoft; B K Pedersen
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.